PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Perampanel - Epilepsy

PAD Profile : Perampanel - Epilepsy Important

Brand Names Include :
Fycompa
Important Information :
Requires specialist initiation and supply for at least 12 weeks prior to a transfer of care to primary care prescribers

Traffic Light Status

Status 1 of 1.

Status :
Blue
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 June 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a change in traffic light status for Perampanel.

Perampanel for treatment in all licensed indications will be given a BLUE (with specialist initiation and supply for at least 12 weeks) traffic light status. 
 

04 April 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN supported the principles of switching from brand to generic medications (not recommended in the elderly) as per national guidelines in September 2013 and the proposed place in therapy of the anti-epileptic drugs which is based on NICE guidance was also discussed at that time. Transfer of care documents supported in March 2015 are attached below. Please note the MHRA categorisations for each drug in the attached guidance (updated January 2014) and in the link below.

Associated BNF Codes

04. Central Nervous System
04.08.01. Control of epilepsy
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More